

## **Ailing Indian pharma industry**

### **What is the issue?**

\n\n

India's champion generic drug industry which has a global presence is losing its sheen.

\n\n

### **What are the causes?**

\n\n

\n

- Indian pharmaceuticals are heavily dependent on the US market.

\n

- Tightening regulations and inspections by international drug control regulators like the US Food and Drug Administration (FDA) is a hindrance.

\n

- FDA has streamlined its processes and is now fast-tracking approvals for new generic drugs which is a good thing.

\n

- However it means that competition in the marketplace has stepped up dramatically as well as prices are getting competitive.

\n

- Indian drug companies are also uncertain due to speculations with Trump's emphasis of manufacturing in America.

\n

\n\n

### **What are the desired actions?**

\n\n

\n

- Indian companies should start making more niche creations that will give them better pricing leverage.

\n

- Need for stepping up R&D spending.

\n

\n\n

\n\n

**Source: The Hindu - BussinessLine**

\n

